前列腺特异性膜抗原正电子发射断层扫描与计算机断层扫描成像确定的前列腺癌近距离放疗后复发模式
基于前瞻性机构试验(NCT02899312)中接受近距离放疗后生化失败的患者,采用[18F]DCFPyL PSMA PET/CT成像分析复发模式。结果显示单药治疗患者以局部失败为主,而外照射联合近距离放疗推量患者以转移性失败为主。
要点
- 单药近距离放疗患者孤立局部复发占54.3%,推量治疗患者仅占12.5%。
- 推量治疗患者转移性失败占68.8%,单药治疗患者占28.6%。
- 局部复发中69.0%位于诊断时肿瘤累及的同一声像活检六分区。
核心结论
- 与既往证据相反,本研究表明前列腺近距离放疗后生化复发患者中,单药治疗者最常见失败部位为局部,而外照射联合近距离放疗推量者最常见为转移性。
研究设计与样本
- 研究为正在进行的机构前瞻性试验(NCT02899312)的一部分,纳入接受近距离放疗(单药或推量)且符合Phoenix定义生化失败的患者。
- 2017年3月至2020年4月间,670例患者接受了[18F]DCFPyL PSMA PET和CT成像,其中93例接受近距离放疗(73例单药,20例推量;19例低剂量率,1例高剂量率)。
- 最终纳入86例[18F]DCFPyL PSMA PET和CT扫描阳性且真实生化失败的患者(扫描前中位PSA 6.0)。
主要发现
- 最常见复发部位为局部,62.8%有局部失败成分(前列腺和/或精囊),46.5%为孤立局部失败无其他部位受累。
- 区域失败发生于40.7%的患者,36.0%有转移性失败。
- 孤立局部复发见于单药治疗患者的54.3% vs 推量治疗患者的12.5%。
- 转移性失败见于单药治疗患者的28.6% vs 推量治疗患者的68.8%。
- 局部复发中69.0%位于诊断时肿瘤累及的同一声像活检六分区,精囊复发患者中76.0%诊断时有前列腺基底部受累。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to characterize the patterns of prostate cancer recurrence after brachytherapy (BT) using 2-(3-[1-carboxy-5-([6-18F-fluoropyridine-3-carbonyl]-amino)-pentyl]-ureido)-pentanedioic acid ([18F]DCFPyL) prostate-specific membrane antigen (PSMA) positron emission tomography (PET) and computed tomography (CT) imaging. METHODS AND MATERIALS: Patients were selected from an ongoing prospective institutional trial investigating the use of [18F]DCFPyL PSMA PET and CT in recurrent prostate cancer (NCT02899312). This report included patients who underwent BT (either monotherapy or boost) and experienced a biochemical failure (BF) defined by the Phoenix definition (prostate-specific antigen [PSA] > 2 ng/mL above nadir). RESULTS: Between March 2017 and April 2020, 670 patients underwent [18F]DCFPyL PSMA PET and CT imaging. Of these 670 patients, 93 were treated with BT; 73 underwent monotherapy, and 20 underwent BT boost (19 low-dose rate and 1 high-dose rate). To report on patterns of recurrence outcomes, 86 patients (median prescan PSA 6.0) with a positive [18F]DCFPyL PSMA PET and CT scan and true BF were included. The most common location of relapse was local; 62.8% had a component of local failure (defined as prostate and/or seminal vesicles), and 46.5% had isolated local failure only, with no other sites of involvement. Regional failure occurred in 40.7% of patients, and 36.0% had metastatic failure. Isolated local recurrence was seen in 54.3% of monotherapy patients versus only in 12.5% of boost patients. Metastatic failure was seen in 28.6% of monotherapy patients versus 68.8% of the boost patients. Local recurrences (69.0%) were found within the same prostate biopsy sextant involved with the tumor at diagnosis, and 76.0% of patients with seminal vesicle recurrences had prostate-base involvement at diagnosis. CONCLUSIONS: Contrary to previous evidence, our study suggests that in prostate BT patients with biochemical recurrence, the most common site of failure is local for the patients treated with monotherapy and metastatic for patients treated with a combination of external beam radiation and BT boost.
引用
- Raman S, Keyes M, Oh J, et al. Patterns of Prostate Cancer Recurrence After Brachytherapy Determined by Prostate-Specific Membrane Antigen-Positron Emission Tomography and Computed Tomography Imaging. Int J Radiat Oncol Biol Phys. 2022. PMID: 34986383. doi:10.1016/j.ijrobp.2021.12.164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。